BCL2 and acute lymphoblastic leukemia: A phase 1 clinical study (NCT03181126) enrolled patients aged older than 4 years with relapse/refractory ALL, including 16 patients with T-ALL and treated patients with the combination venetoclax and navitoclax (a BCL-2/BCL-XL/BCL-W inhibitor).